Nano Magic Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nano Magic Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $7.88M | Jun 15, 2018 |
| FY2017 | Dec 31, 2016 | $8.12M | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $9.69M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $9.95M | Mar 30, 2016 |
| FY2013 | Dec 31, 2013 | $727.7K | Feb 25, 2014 |
| FY2013 | Sep 30, 2013 | $1.18M | Feb 25, 2014 |
| FY2013 | Jun 30, 2013 | $1.07M | Feb 25, 2014 |
| FY2013 | Mar 31, 2013 | $948.7K | Feb 25, 2014 |
| FY2013 | Dec 31, 2012 | $980.8K | Feb 25, 2014 |
| FY2013 | Sep 30, 2012 | $705.5K | Feb 25, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.78M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $2.58M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $4.31M | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | $4.76M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $2.44M | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $4.50M | May 13, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $363.9K | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $96.2K | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $1.66M | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | $1.66M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $323.9K | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $1.05M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.27M | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.81M | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $3.34M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $4.30M | Mar 30, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($2.86M) | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | ($2.10M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($1.57M) | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | ($781.1K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($965.0K) | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $22.1K | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($687.1K) | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | ($556.0K) | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | ($1.87M) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($2.37M) | Mar 30, 2016 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($2.84M) | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | ($3.35M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($1.63M) | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | ($792.6K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($1.03M) | May 28, 2021 |
| FY2019 | Dec 31, 2018 | ($40.4K) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($719.9K) | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | ($747.0K) | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | ($1.76M) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($2.29M) | Mar 30, 2016 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $47.4K | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $16.8K | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $34.9K | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | $56.8K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $68.5K | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $60.8K | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $286.4K | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $290.4K | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $744.3K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $607.0K | Mar 30, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $993.0K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $996.2K | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $747.9K | Apr 10, 2015 |
| FY2013 | Dec 31, 2012 | $3.80M | Feb 25, 2014 |
| FY2013 | Dec 31, 2011 | $3.17M | Feb 25, 2014 |
| FY2012 | Dec 31, 2010 | $2.90M | Mar 1, 2013 |
| FY2011 | Dec 31, 2009 | $2.54M | Mar 1, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($1.54M) | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | ($1.71M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($1.38M) | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | ($2.00M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($878.7K) | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $155.9K | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $438.6K | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $444.5K | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | ($804.2K) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $547.6K | Mar 30, 2016 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $9.4K | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $4.9K | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $127.0K | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | $143.5K | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $11.1K | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $3.9K | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $6.1K | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $4.0K | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $248.1K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $229.8K | Mar 30, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $3.52M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $4.09M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $4.11M | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | $4.79M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.32M | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $1.60M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.18M | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $2.79M | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $3.58M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $4.43M | Mar 30, 2016 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.21M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $2.47M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | $2.19M | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | $3.39M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.77M | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $2.44M | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.28M | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $3.37M | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $3.85M | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $3.21M | Mar 30, 2016 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.31M | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | $1.62M | Apr 3, 2024 |
| FY2023 | Dec 31, 2021 | $1.92M | Apr 3, 2024 |
| FY2022 | Dec 31, 2020 | $1.40M | Apr 11, 2023 |
| FY2021 | Dec 31, 2019 | ($446.9K) | Mar 30, 2022 |
| FY2020 | Dec 31, 2018 | ($837.6K) | May 28, 2021 |
| FY2019 | Dec 31, 2017 | ($1.10M) | May 13, 2020 |
| FY2018 | Dec 31, 2016 | ($578.1K) | Nov 14, 2019 |
| FY2017 | Dec 31, 2015 | ($272.3K) | Jun 15, 2018 |
| FY2016 | Dec 31, 2014 | $1.22M | Mar 29, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | ($15.00M) | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | ($12.15M) | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | ($10.05M) | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | ($8.47M) | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | ($7.69M) | May 28, 2021 |
| FY2019 | Dec 31, 2018 | ($6.72M) | May 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.59M) | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | ($5.90M) | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | ($5.34M) | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | ($3.47M) | Mar 30, 2016 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $288.1K | May 28, 2021 |
| FY2020 | Dec 31, 2019 | $216.8K | May 28, 2021 |
| FY2019 | Dec 31, 2018 | $211.5K | May 13, 2020 |
| FY2018 | Dec 31, 2017 | $138.3K | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | $189.1K | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | $262.5K | Mar 29, 2017 |
| FY2016 | Dec 31, 2014 | $464.7K | Mar 29, 2017 |
| FY2015 | Dec 31, 2013 | $100.4K | Mar 30, 2016 |
| FY2014 | Dec 31, 2012 | $1.54M | Apr 10, 2015 |
| FY2013 | Dec 31, 2011 | $3.07M | Feb 25, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $96.6K | Mar 30, 2022 |
| FY2020 | Dec 31, 2020 | $275.9K | May 28, 2021 |
| FY2019 | Dec 31, 2019 | $174.8K | May 13, 2020 |
| FY2018 | Dec 31, 2018 | $203.4K | Nov 14, 2019 |
| FY2017 | Dec 31, 2017 | $277.3K | Jun 15, 2018 |
| FY2016 | Dec 31, 2016 | $356.6K | Mar 29, 2017 |
| FY2015 | Dec 31, 2015 | $386.5K | Mar 30, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | May 28, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 13, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | (1) | Mar 30, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 0 | May 28, 2021 |
| FY2019 | Dec 31, 2018 | 0 | May 13, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Nov 14, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Jun 15, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | (1) | Mar 30, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 13.43M | Apr 3, 2024 |
| FY2023 | Sep 30, 2023 | 136,482 | Apr 3, 2024 |
| FY2023 | Dec 31, 2022 | 10.72M | Apr 3, 2024 |
| FY2022 | Dec 31, 2021 | 9.70M | Apr 11, 2023 |
| FY2021 | Dec 31, 2020 | 8.46M | Mar 30, 2022 |
| FY2020 | Dec 31, 2019 | 6.22M | May 28, 2021 |
| FY2013 | Dec 31, 2013 | 147.83M | Feb 25, 2014 |
| FY2013 | Dec 31, 2012 | 119.70M | Feb 25, 2014 |
| FY2012 | Dec 31, 2011 | 118.92M | Mar 1, 2013 |
| FY2011 | Dec 31, 2010 | 109.97M | Mar 1, 2012 |